{"meta":{"query_hash":"7626a6004b58","filters":{"venue":"Expert Opinion on Therapeutic Patents"},"cohort_total":45,"direct_labels_cover":0,"predictions_cover":45,"exported":45,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7626a6004b58","api":"https://metacan.xera.ac/api/v1/cohort?venue=Expert+Opinion+on+Therapeutic+Patents"},"results":[{"id":"W1769059961","doi":"10.1517/13543776.2015.1086749","title":"A STAT inhibitor patent review: progress since 2011","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dairy Farmers of Ontario; University of Toronto","funders":"","keywords":"STAT5; stat; SH2 domain; Computational biology; STAT3; Cancer research; Biology; Kinase; Phosphorylation; Genetics","score_opus":0.30696338683707014,"score_gpt":0.4409019624140757,"score_spread":0.13393857557700556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769059961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.7076246e-7,0.991973,0.000020881389,0.000789149,0.0036439747,0.002844051,0.00012633135,0.00018328508,0.00041867638],"genre_scores_gemma":[0.000008359785,0.9934686,0.000095512834,0.0024902802,0.0011275184,0.00092019426,0.0010812149,0.00017153625,0.00063681067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961602,0.00033406046,0.0011894705,0.00084498915,0.0009255445,0.00054569944],"domain_scores_gemma":[0.9974647,0.00007492247,0.00066207256,0.0010110363,0.0003598611,0.0004274095],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004167905,0.000831725,0.0024684337,0.00028367748,0.000116723786,0.000047100268,0.00031639155,0.00034753335,0.0005613154],"category_scores_gemma":[0.000041515534,0.00055751175,0.0009252463,0.000277625,0.000100325815,0.0000996859,0.00009733359,0.00076473557,0.001903585],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007978442,0.0007211172,0.0000037076047,0.007904183,0.00037982865,0.000031561456,0.00007583486,4.28322e-8,0.000007451281,0.00003246561,0.048582546,0.94218147],"study_design_scores_gemma":[0.0007249439,0.0009592096,0.0000027728286,0.12250371,0.00019730462,0.00017939325,0.000013566654,0.000006679323,0.000025971816,0.000008507209,0.87490773,0.00047020608],"about_ca_topic_score_codex":0.00002347776,"about_ca_topic_score_gemma":2.4432956e-7,"teacher_disagreement_score":0.94171125,"about_ca_system_score_codex":0.00050740765,"about_ca_system_score_gemma":0.0005647183,"threshold_uncertainty_score":0.9996876},"labels":[],"label_agreement":null},{"id":"W1769626824","doi":"10.1517/13543776.12.4.513","title":"Recent progress in 5-HT<sub>6</sub>receptor antagonists for the treatment of CNS diseases","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Neurotransmitter Receptor Influence on Behavior","field":"Neuroscience","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Serotonergic; Medicine; Mechanism (biology); 5-HT6 receptor; Schizophrenia (object-oriented programming); Neuroscience; Intensive care medicine; Pharmacology; Psychiatry; 5-HT receptor; Psychology; Receptor; Serotonin; Internal medicine; Epistemology; Philosophy","score_opus":0.11949921082770117,"score_gpt":0.3431025908647595,"score_spread":0.22360338003705837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1769626824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756405,0.014219184,0.00003502471,0.0035482915,0.0028201728,0.003353795,0.00022889953,0.00013098307,0.000023175056],"genre_scores_gemma":[0.9415299,0.05535981,0.000024205747,0.0012121665,0.00012063716,0.0016500516,0.000010889975,0.00006127591,0.00003103211],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976973,0.00021784757,0.00045731524,0.0006331628,0.0004896097,0.0005047532],"domain_scores_gemma":[0.9988041,0.00029840466,0.00017890033,0.0005490881,0.000044591176,0.00012491645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059577163,0.00034944582,0.00032389868,0.00013329738,0.00017711373,0.000053251137,0.0004513143,0.00007950184,0.00013517201],"category_scores_gemma":[0.00002228302,0.00023370006,0.00019842997,0.00033092592,0.00026695084,0.00013590413,0.000018371427,0.00009448835,0.00011581609],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032891365,0.0034023053,0.0072396,0.000009829423,0.000015782414,0.000004410558,0.0013336554,0.000007791472,0.2989382,0.00005043319,0.00023773748,0.6884313],"study_design_scores_gemma":[0.0025274188,0.0015136173,0.011380065,0.000073197654,0.000008511738,0.0000043424975,0.000050157112,0.000403145,0.86695814,0.000026281874,0.11677166,0.0002834587],"about_ca_topic_score_codex":0.0000037773646,"about_ca_topic_score_gemma":8.1813806e-7,"teacher_disagreement_score":0.68814784,"about_ca_system_score_codex":0.00016634958,"about_ca_system_score_gemma":0.000021896514,"threshold_uncertainty_score":0.95300114},"labels":[],"label_agreement":null},{"id":"W1967410304","doi":"10.1517/13543776.2015.1010512","title":"Phosphorus-containing nanoparticles: biomedical patents review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Nanotechnology; Phosphorus; Nanoparticle; Chemistry; Business; Materials science; Organic chemistry","score_opus":0.14211581921221567,"score_gpt":0.379793716350022,"score_spread":0.23767789713780635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967410304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010091551,0.9922126,0.000025278283,0.00021022689,0.005101702,0.0017819508,0.0001219466,0.00034029566,0.00010509427],"genre_scores_gemma":[0.00020807901,0.99482894,0.00012871751,0.0030829383,0.00045638476,0.00074382283,0.00027388195,0.0001881899,0.0000890312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925926,0.0012284715,0.0018290683,0.0013736225,0.0017615943,0.0012146821],"domain_scores_gemma":[0.9964946,0.0002594208,0.00087896775,0.0014367288,0.00021947589,0.00071084494],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019337873,0.0010708399,0.002780486,0.00024238457,0.00022255891,0.00014730888,0.0013505754,0.00047410204,0.0006600137],"category_scores_gemma":[0.00015879766,0.0007867206,0.0006336049,0.00079798006,0.0002623924,0.0002649223,0.00030790584,0.00049925694,0.008551945],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007876107,0.00060307776,0.0000036460642,0.0032190194,0.000119889235,0.00004856682,0.00015557282,3.889264e-7,0.0007812503,0.000047064077,0.007128306,0.9878145],"study_design_scores_gemma":[0.0008516594,0.0005920751,0.0000010046472,0.052183546,0.00011870643,0.000043466775,0.00003674597,0.000018292447,0.00088335265,0.000039976592,0.94438773,0.00084345933],"about_ca_topic_score_codex":0.000048917413,"about_ca_topic_score_gemma":1.8262746e-7,"teacher_disagreement_score":0.986971,"about_ca_system_score_codex":0.000647029,"about_ca_system_score_gemma":0.0006777587,"threshold_uncertainty_score":0.9994584},"labels":[],"label_agreement":null},{"id":"W1969081293","doi":"10.1517/13543776.2014.898753","title":"LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)","year":2014,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Integrase; Allosteric regulation; Integrase inhibitor; Human immunodeficiency virus (HIV); Biology; Computational biology; Pharmacology; Virology; Enzyme; Antiretroviral therapy; Biochemistry; Viral load","score_opus":0.07985944761990504,"score_gpt":0.35796034411425753,"score_spread":0.2781008964943525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969081293","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027005035,0.99329984,0.00007291196,0.00079822645,0.0014674751,0.0032529654,0.000115072784,0.00008105658,0.00090972916],"genre_scores_gemma":[0.000045438635,0.98798364,0.00013931372,0.0010709554,0.00039213433,0.00067181187,0.0052933786,0.00017580477,0.0042274892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952361,0.0003151047,0.0018660612,0.0010041107,0.00093136233,0.00064729166],"domain_scores_gemma":[0.99695694,0.00016408772,0.0010231138,0.0013018476,0.00018472513,0.00036926905],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005529197,0.0011986787,0.004222106,0.0005401428,0.000094864234,0.000022942922,0.00038908306,0.0004543511,0.0004943234],"category_scores_gemma":[0.00005355698,0.0007783201,0.0013371041,0.00050502113,0.00012158777,0.000069340065,0.000121474266,0.0005633868,0.0034239052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057310404,0.00088627,0.00011701457,0.027199103,0.0014611942,0.000030453639,0.00018264638,6.980732e-8,0.000003534401,0.000019552539,0.10727623,0.8627666],"study_design_scores_gemma":[0.0013437838,0.00028206845,0.000019915702,0.17553495,0.0006157666,0.00005520739,0.0000125862025,0.000007646641,0.000040294042,0.000004595188,0.8215383,0.000544847],"about_ca_topic_score_codex":0.000024552817,"about_ca_topic_score_gemma":7.5642697e-7,"teacher_disagreement_score":0.8622218,"about_ca_system_score_codex":0.0005001365,"about_ca_system_score_gemma":0.00049074506,"threshold_uncertainty_score":0.9994668},"labels":[],"label_agreement":null},{"id":"W1969226240","doi":"10.1517/13543776.12.8.1237","title":"Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Endothelium; Pharmacology; Medicine; Vascular smooth muscle; Endothelial dysfunction; Angiogenesis; Fibrinolysis; Angiotensin II; Platelet; Immunology; Internal medicine; Blood pressure","score_opus":0.07753051824902753,"score_gpt":0.31534657214179657,"score_spread":0.23781605389276905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969226240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48485264,0.17510079,0.29421785,0.011010581,0.018566245,0.009482446,0.0005468276,0.00077205076,0.0054505733],"genre_scores_gemma":[0.98541725,0.006205312,0.0003873649,0.00659407,0.00055513653,0.00019869056,0.0001466497,0.0000672787,0.0004282576],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983878,0.0001011583,0.0003119957,0.00054747984,0.00024681,0.00040476833],"domain_scores_gemma":[0.9991711,0.00003268376,0.0001420562,0.0004291123,0.000121288715,0.00010378043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017983792,0.00029882038,0.0002422183,0.00007747146,0.00019886905,0.000051855477,0.0002674602,0.00024110323,0.00017572871],"category_scores_gemma":[0.000014206122,0.00024957387,0.00022197266,0.00006777468,0.00006549352,0.000014329674,0.00004384619,0.000112669106,0.000052225372],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022478841,0.00056755636,0.000077356795,0.00000925501,0.00027279035,9.1984583e-7,0.00027038986,0.000094395,0.9715186,0.0009241607,0.0023059486,0.023733893],"study_design_scores_gemma":[0.013467789,0.0043244036,0.0023454197,0.000065805885,0.000059232374,0.000061974635,0.0011027262,0.008694594,0.36733112,0.0014592996,0.5996974,0.0013902113],"about_ca_topic_score_codex":0.000015151446,"about_ca_topic_score_gemma":0.0000021238063,"teacher_disagreement_score":0.6041874,"about_ca_system_score_codex":0.000030503259,"about_ca_system_score_gemma":0.00003630345,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W1982970232","doi":"10.1517/13543776.2013.780598","title":"Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 – 2013)","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Enzyme function and inhibition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":295,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Carbonic anhydrase; Pharmacology; Chlorthalidone; Chemistry; Furosemide; Diuretic; Hydrochlorothiazide; Bumetanide; Drug; Acetazolamide; Medicine; Internal medicine; Blood pressure; Enzyme; Biochemistry","score_opus":0.0921937601477758,"score_gpt":0.33820708731809257,"score_spread":0.24601332717031676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982970232","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011168005,0.9972133,0.00004572007,0.00026255284,0.0010535895,0.0011746469,0.000040522937,0.000037070142,0.00016145085],"genre_scores_gemma":[0.000032025026,0.99343264,0.000042452415,0.0023403144,0.00084559154,0.00049971306,0.0016582859,0.000095319185,0.001053636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99780715,0.0002892777,0.00047643893,0.00075993926,0.0003040454,0.00036317325],"domain_scores_gemma":[0.99867636,0.000015281546,0.0003469309,0.00063446275,0.00012020731,0.00020675179],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015248652,0.0006398594,0.00078953186,0.00011140082,0.00011880618,0.000074513315,0.00016528675,0.00055493653,0.00009918643],"category_scores_gemma":[0.000012189364,0.0004320159,0.0002607442,0.000164752,0.000091918846,0.000014761739,0.000070695976,0.00040943356,0.000065737935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075769705,0.00026199798,0.0000034869836,0.008278318,0.000398864,0.000012480116,0.000047381855,4.9803117e-7,0.00041626784,0.000031272815,0.08117785,0.9092958],"study_design_scores_gemma":[0.00049127295,0.0006085711,0.0000019848958,0.0388214,0.000065110886,0.00017722163,0.000012167558,0.0000028942695,0.00018678332,0.000003117493,0.9591234,0.0005060948],"about_ca_topic_score_codex":0.000005905185,"about_ca_topic_score_gemma":0.000001928009,"teacher_disagreement_score":0.9087897,"about_ca_system_score_codex":0.000069754075,"about_ca_system_score_gemma":0.00012326051,"threshold_uncertainty_score":0.99981314},"labels":[],"label_agreement":null},{"id":"W1989556851","doi":"10.1517/13543770903059125","title":"The search for new COX-2 inhibitors: a review of 2002 – 2008 patents","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado de Minas Gerais; Merck Canada; Conselho Nacional de Desenvolvimento Científico e Tecnológico","keywords":"Naproxen; Valdecoxib; Celecoxib; Medicine; Ibuprofen; Pharmacology; Inflammation; Cyclooxygenase; Nabumetone; Aspirin; Etoricoxib; Nonsteroidal; Chemistry; Enzyme; Rofecoxib; Internal medicine; Biochemistry","score_opus":0.13245205505203045,"score_gpt":0.4087917491154659,"score_spread":0.27633969406343545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989556851","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012498012,0.9903876,0.00003330669,0.0007756657,0.002745703,0.005725929,0.000051676387,0.000059048845,0.00021978484],"genre_scores_gemma":[0.0000034664117,0.9938167,0.000052436295,0.0023451385,0.001676704,0.00048584142,0.0003057053,0.00013177404,0.0011822619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957235,0.00049613725,0.001403973,0.0006257436,0.0010185952,0.0007320367],"domain_scores_gemma":[0.9970599,0.00054532127,0.0006808031,0.0010629512,0.00026239987,0.0003886419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010857895,0.0007551081,0.0025431705,0.00020892415,0.0002097867,0.000026206133,0.0004835394,0.0004677392,0.000115209696],"category_scores_gemma":[0.00015614384,0.00042904963,0.0012749941,0.0004043567,0.00010649958,0.000044097636,0.000056814508,0.0005581232,0.00018867222],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012877358,0.00019318186,0.000004074918,0.027492365,0.00034958342,0.000007071746,0.000072749135,3.8424005e-8,0.0000044410267,0.00003976029,0.065327935,0.90638],"study_design_scores_gemma":[0.0012120829,0.0009546479,0.000011886423,0.18495949,0.00015780835,0.000033876368,0.000007519921,0.0000053162635,0.00009456919,0.000011508242,0.8122378,0.0003135121],"about_ca_topic_score_codex":0.000017564218,"about_ca_topic_score_gemma":3.0620512e-7,"teacher_disagreement_score":0.90606654,"about_ca_system_score_codex":0.0002214402,"about_ca_system_score_gemma":0.00081216067,"threshold_uncertainty_score":0.9998161},"labels":[],"label_agreement":null},{"id":"W1993341051","doi":"10.1517/13543776.12.12.1795","title":"Developments in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital; University of Toronto","funders":"","keywords":"MAPK/ERK pathway; Kinase; Signal transduction; Cancer research; Extracellular; Protein kinase A; Mitogen-activated protein kinase; Immune system; ASK1; Biology; Cell biology; Medicine; Immunology; Mitogen-activated protein kinase kinase","score_opus":0.08536307861861339,"score_gpt":0.27448759424772895,"score_spread":0.18912451562911556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993341051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98689353,0.012304347,0.00001037234,0.000079095465,0.0003103621,0.00034216937,0.00001049633,0.0000038062024,0.000045801484],"genre_scores_gemma":[0.9930244,0.006458093,0.000018554674,0.00021734014,0.000059591348,0.00008486629,0.000046835314,0.00001416909,0.00007616086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906605,0.00014043385,0.00021945777,0.00027671596,0.00010818216,0.0001891532],"domain_scores_gemma":[0.9995669,0.000021403297,0.000055818557,0.0002786004,0.000013880753,0.0000633853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007261688,0.00018053518,0.00013839353,0.00006765675,0.000035987545,0.000013667496,0.000108687105,0.00008060806,0.0000069180487],"category_scores_gemma":[0.000008615671,0.00011494089,0.00005320706,0.00007732253,0.000030464704,0.000005820984,0.000017102084,0.000039098028,0.000003673096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044857038,0.0021011364,0.0567137,0.000012569454,0.00006518504,0.000018067774,0.0065115304,0.000005407533,0.8114421,0.000074761985,0.00009949125,0.12250751],"study_design_scores_gemma":[0.005654291,0.0022799217,0.12832373,0.00014238946,0.0000046443142,0.0000067407127,0.0011432947,0.00021821025,0.7339102,0.00005324532,0.12773219,0.00053113885],"about_ca_topic_score_codex":0.000053487704,"about_ca_topic_score_gemma":0.000012510702,"teacher_disagreement_score":0.1276327,"about_ca_system_score_codex":0.000025353396,"about_ca_system_score_gemma":0.000015778021,"threshold_uncertainty_score":0.46871537},"labels":[],"label_agreement":null},{"id":"W2006746802","doi":"10.1517/13543776.2010.505604","title":"17β-Hydroxysteroid dehydrogenase inhibitors: a patent review","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Dehydrogenase; Hydroxysteroid dehydrogenase; Chemistry; Biochemistry; Enzyme; Pharmacology; Biology","score_opus":0.07400655074951908,"score_gpt":0.35291488047837893,"score_spread":0.27890832972885987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006746802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035688565,0.9949639,0.000016002,0.000077264485,0.0026150967,0.0018814739,0.00004825469,0.00006315517,0.00029919078],"genre_scores_gemma":[0.00005407098,0.9943662,0.000032038843,0.0016791631,0.0010682365,0.0006303394,0.001667978,0.00020435061,0.00029759592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963519,0.0005470885,0.000925054,0.001090835,0.00044602156,0.0006391142],"domain_scores_gemma":[0.99772805,0.00003413281,0.0005513051,0.0012918732,0.00007402048,0.00032063544],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00036542458,0.0009938823,0.0014880382,0.00014185681,0.0001571769,0.000046136967,0.0006614646,0.0013234221,0.000051656196],"category_scores_gemma":[0.00004226672,0.0007132781,0.0011847958,0.00025363112,0.00010191866,0.000006194488,0.00018090144,0.000879685,0.0005924186],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003420466,0.00031556017,0.0000016898157,0.0039241165,0.00051336514,0.000019857895,0.00001703438,2.4043092e-7,0.002186296,0.0000110444535,0.005852098,0.9871245],"study_design_scores_gemma":[0.00049578754,0.00061235094,3.1993176e-7,0.028271394,0.00010807255,0.00015795948,0.0000024806168,0.0000031342922,0.002293726,0.0000050830317,0.96728253,0.0007671298],"about_ca_topic_score_codex":0.000007071246,"about_ca_topic_score_gemma":3.5918222e-7,"teacher_disagreement_score":0.9863574,"about_ca_system_score_codex":0.000065270935,"about_ca_system_score_gemma":0.0002141916,"threshold_uncertainty_score":0.99997306},"labels":[],"label_agreement":null},{"id":"W2010505546","doi":"10.1517/13543776.2011.593510","title":"Cyclooxygenase-2 inhibitors: a literature and patent review (2009 – 2010)","year":2011,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"","keywords":"Cyclooxygenase; Chemistry; Pharmacology; Medicine; Biochemistry; Enzyme","score_opus":0.1377688192194239,"score_gpt":0.3557674840241276,"score_spread":0.2179986648047037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010505546","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006731557,0.9926293,0.0000037063255,0.00021455552,0.0037297567,0.0030243953,0.00007433055,0.00013746099,0.00017975882],"genre_scores_gemma":[0.0000075721096,0.9923183,0.000038416172,0.0042821667,0.0013249228,0.00062614825,0.0006706712,0.00017500656,0.00055681274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964285,0.0004990937,0.0010059499,0.0009277641,0.00051502517,0.0006236817],"domain_scores_gemma":[0.9977158,0.00012527392,0.00052581384,0.0009855744,0.00013163433,0.00051592715],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049750874,0.0010535467,0.0027001824,0.0003416496,0.00012558475,0.00004649394,0.0002401025,0.0007606775,0.00018117133],"category_scores_gemma":[0.00008445723,0.0006770462,0.0007619514,0.00038916545,0.00009160435,0.0000794238,0.000090170215,0.0008990432,0.0003560781],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006265724,0.00024061064,0.000009578467,0.039362084,0.00035696593,0.00010456237,0.00030916627,2.0131872e-9,0.000004140814,0.000043099844,0.01427287,0.94523424],"study_design_scores_gemma":[0.00069580297,0.0004944174,0.000027548935,0.24564254,0.0001936006,0.00027291026,0.0000036446243,7.863835e-7,0.000013730427,0.000015815374,0.7521511,0.0004881155],"about_ca_topic_score_codex":0.000011651255,"about_ca_topic_score_gemma":2.802449e-7,"teacher_disagreement_score":0.94474614,"about_ca_system_score_codex":0.0001451713,"about_ca_system_score_gemma":0.00025153894,"threshold_uncertainty_score":0.99956805},"labels":[],"label_agreement":null},{"id":"W2013882224","doi":"10.1517/13543770802554275","title":"Recently patented agents with possible antipsychotic indication","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"","keywords":"Antipsychotic; Agonism; Medicine; Mechanism (biology); Pharmacology; Atypical antipsychotic; Pharmacodynamics; Antagonism; Mechanism of action; Psychiatry; Receptor; Schizophrenia (object-oriented programming); Biology; Internal medicine; Political science; Pharmacokinetics","score_opus":0.12288572048776221,"score_gpt":0.35694285539525683,"score_spread":0.23405713490749464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013882224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908455,0.0031266243,0.00021856221,0.0027353256,0.00050875585,0.0011452852,0.00001028887,0.00018120302,0.0012284445],"genre_scores_gemma":[0.9890221,0.008062585,0.0005505246,0.0014303918,0.000114238755,0.00012382572,0.00021380186,0.000045030825,0.00043750255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980613,0.00009387456,0.0002386271,0.00043043145,0.0007566246,0.0004191535],"domain_scores_gemma":[0.9989766,0.000028746508,0.00009641204,0.00048125585,0.00010833761,0.00030865546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080533915,0.00024658424,0.0002637486,0.00022284829,0.00022101078,0.000018130662,0.00012897258,0.00009051575,0.00035189817],"category_scores_gemma":[0.000012664654,0.00016370324,0.00008588939,0.00035450608,0.00009831167,0.000089489826,0.000017386334,0.00019085166,0.00048835884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0746017,0.010876208,0.60165614,0.000068755005,0.0023162013,0.0008522138,0.00303718,0.000011222536,0.0069522955,0.0005091871,0.00874103,0.29037786],"study_design_scores_gemma":[0.0145944245,0.003324629,0.96566427,0.00031146407,0.000013938681,0.00032162544,0.0001031962,0.00032765293,0.009012544,0.00012910149,0.005927263,0.0002698718],"about_ca_topic_score_codex":0.00003269333,"about_ca_topic_score_gemma":0.0000013966101,"teacher_disagreement_score":0.36400813,"about_ca_system_score_codex":0.00015012299,"about_ca_system_score_gemma":0.00015235657,"threshold_uncertainty_score":0.6675624},"labels":[],"label_agreement":null},{"id":"W2018494913","doi":"10.1517/13543776.2014.851669","title":"An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 – 2013)","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aboriginal Affairs Northern Dev Canada","funders":"Glenmark Pharmaceuticals; Pfizer","keywords":"Adverse effect; Pharmacology; Medicine; Small molecule; Fatty liver; Bioinformatics; Biology; Cancer research; Biochemistry; Internal medicine","score_opus":0.27537770642034,"score_gpt":0.4409548434803954,"score_spread":0.1655771370600554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018494913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009078462,0.99310404,0.000042892494,0.00031797306,0.0032064859,0.002861996,0.00017429318,0.00015540968,0.000046114663],"genre_scores_gemma":[0.0001408415,0.9964692,0.00030700045,0.0010237184,0.00048612058,0.000362712,0.0009303989,0.00022986802,0.000050158567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937077,0.0015418398,0.001462124,0.0010462645,0.0010263743,0.0012156528],"domain_scores_gemma":[0.9964692,0.00021110746,0.00087810593,0.0014427276,0.00027435724,0.00072448497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005852445,0.0009874917,0.002239822,0.0006060062,0.00024554614,0.00011667604,0.0010206865,0.00077132665,0.0003902037],"category_scores_gemma":[0.000049959133,0.0007380743,0.00073455967,0.0006208769,0.00017927025,0.00020966273,0.00011106587,0.0010746921,0.0006997753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020581466,0.0010180535,0.000010111969,0.005871814,0.00022472197,0.000008823502,0.00025963812,9.343423e-7,0.00037030043,0.00004041603,0.012916695,0.9790727],"study_design_scores_gemma":[0.0012800499,0.002233378,0.00003977494,0.021409651,0.00005403929,0.000019891557,0.00009008932,0.00010979303,0.0019545346,0.000047843434,0.9719099,0.0008510706],"about_ca_topic_score_codex":0.0012258894,"about_ca_topic_score_gemma":0.000011520882,"teacher_disagreement_score":0.9782216,"about_ca_system_score_codex":0.0003758022,"about_ca_system_score_gemma":0.0002793035,"threshold_uncertainty_score":0.999507},"labels":[],"label_agreement":null},{"id":"W2020008986","doi":"10.1517/13543776.12.8.1215","title":"Gangliosides: therapeutic agents or therapeutic targets?","year":2002,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Neurodegeneration; Drug; Computational biology; Glycolipid; Drug discovery; Biology; Neuroscience; Pharmacology; Medicine; Immunology; Bioinformatics; Disease","score_opus":0.11059924822502899,"score_gpt":0.3483887617806951,"score_spread":0.23778951355566613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020008986","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31106627,0.5016664,0.03891773,0.032386072,0.02263851,0.018729074,0.00044025562,0.0020782666,0.072077364],"genre_scores_gemma":[0.9721002,0.0121352095,0.000109420405,0.008624076,0.00047531817,0.00022400511,0.00012472951,0.00010559837,0.006101425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706465,0.00031805362,0.0004231444,0.0007717247,0.00068126345,0.0007411643],"domain_scores_gemma":[0.99855596,0.000040364055,0.00013740725,0.0008789728,0.00014083955,0.00024647245],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024261817,0.0004558364,0.0002989826,0.00018182896,0.0003022492,0.000100414465,0.0005819891,0.00030634677,0.0035920676],"category_scores_gemma":[0.00004577645,0.00034442235,0.0002210965,0.00030974613,0.00013432195,0.0000177347,0.000104677325,0.00025585084,0.00086441636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025482231,0.0027450195,0.0027853337,0.000055087537,0.0011561562,0.000055062363,0.0018910973,0.00013077803,0.3633942,0.00078222394,0.0327024,0.59175444],"study_design_scores_gemma":[0.0032955296,0.0020188387,0.0033616289,0.00006475733,0.000008112932,0.00004362413,0.0003011921,0.0024848483,0.093373306,0.00027814513,0.8939824,0.00078760553],"about_ca_topic_score_codex":0.000019314646,"about_ca_topic_score_gemma":0.0000047814297,"teacher_disagreement_score":0.86128,"about_ca_system_score_codex":0.000063547355,"about_ca_system_score_gemma":0.00004736114,"threshold_uncertainty_score":0.9999135},"labels":[],"label_agreement":null},{"id":"W2020159664","doi":"10.1517/13543776.2010.533171","title":"Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Natural Antidiabetic Agents Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Calgary; F. Hoffmann-La Roche","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Macrovascular disease; Insulin resistance; Glycemic; Insulin; Disease; Diabetic retinopathy; Nephropathy; Retinopathy; Obesity; Internal medicine; Endocrinology; Intensive care medicine","score_opus":0.161926584440197,"score_gpt":0.38115649454428646,"score_spread":0.21922991010408946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020159664","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033539976,0.9962379,0.0000036880488,0.00085531553,0.0005622059,0.0018913435,0.00006170313,0.0000229532,0.000029508592],"genre_scores_gemma":[0.0028747127,0.99386233,0.00006005901,0.0018186099,0.00010572377,0.0004509411,0.0007497451,0.00003339684,0.000044470984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969292,0.0005323228,0.0010213254,0.00051631685,0.00060049695,0.00040030578],"domain_scores_gemma":[0.99822813,0.00026623395,0.00058817875,0.00063415477,0.00019030734,0.00009300458],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005799929,0.000573984,0.0026402336,0.00039829224,0.00009098925,0.000030062456,0.00026852798,0.00032350977,0.000052189615],"category_scores_gemma":[0.00013312722,0.0002916213,0.00061176793,0.001122826,0.00015747192,0.000063251704,0.00007362472,0.0007821861,0.000010595363],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004683311,0.0009246894,0.0028177914,0.035703134,0.0033540046,0.000015586911,0.0019128765,1.9348079e-7,0.000023716198,0.0000394964,0.0020282143,0.95313346],"study_design_scores_gemma":[0.0008841226,0.00038411646,0.013886463,0.18404539,0.0023639798,0.000012453257,0.00008515764,0.000051736388,0.000023790517,0.00003702188,0.7977059,0.00051989657],"about_ca_topic_score_codex":0.000012403544,"about_ca_topic_score_gemma":0.0000027077,"teacher_disagreement_score":0.9526136,"about_ca_system_score_codex":0.00004955644,"about_ca_system_score_gemma":0.00005188303,"threshold_uncertainty_score":0.99995357},"labels":[],"label_agreement":null},{"id":"W2027041011","doi":"10.1517/13543776.17.3.277","title":"Therapeutic advances in the treatment of osteoporosis","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Osteoporosis; Medicine; Strontium ranelate; Anabolic Agents; Bisphosphonate; Teriparatide; Pharmacology; Intensive care medicine; Internal medicine; Bone mineral","score_opus":0.0757609616107818,"score_gpt":0.38584861331014875,"score_spread":0.3100876516993669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027041011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7452036,0.23730859,0.00024027949,0.004376193,0.0020859332,0.0034558133,0.000019323657,0.000108663044,0.0072015864],"genre_scores_gemma":[0.95988053,0.036724195,0.00008981872,0.0029936018,0.00007190817,0.000094560615,0.000029827186,0.000021560936,0.00009401141],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99846584,0.00009018596,0.0004078673,0.00025903923,0.00039242703,0.00038465273],"domain_scores_gemma":[0.9991625,0.00017174662,0.00012136743,0.00040525335,0.000037207083,0.000101930316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022762013,0.00022157532,0.00033794067,0.0001472195,0.000072609946,0.0000059960557,0.00010051766,0.000092700466,0.000052028267],"category_scores_gemma":[0.0000045577717,0.00012251489,0.00012950531,0.0002537407,0.00006438855,0.00006020985,0.0000041163844,0.00008362699,0.000039511557],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016549577,0.0043038097,0.06786903,0.000020561112,0.00009823327,0.000022253467,0.0060282983,0.0000014304215,0.0005270833,0.00031122396,0.000018286142,0.9191448],"study_design_scores_gemma":[0.013143953,0.0113278795,0.55795544,0.00024046442,0.000032769014,0.00004851845,0.0026607935,0.00004070513,0.014048377,0.00060349685,0.39961794,0.00027967445],"about_ca_topic_score_codex":0.00016212735,"about_ca_topic_score_gemma":0.000023644954,"teacher_disagreement_score":0.91886514,"about_ca_system_score_codex":0.000163639,"about_ca_system_score_gemma":0.000045289373,"threshold_uncertainty_score":0.49960122},"labels":[],"label_agreement":null},{"id":"W2031439958","doi":"10.1517/13543776.11.4.625","title":"Novel serotonergic and non-serotonergic migraine headache therapies","year":2001,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IDELIX Software (Canada)","funders":"","keywords":"Sumatriptan; Migraine; Rizatriptan; Zolmitriptan; Triptans; Medicine; Serotonergic; Pharmacology; Methysergide; Intensive care medicine; Neuroscience; Serotonin; Psychology; Agonist; Anesthesia; Internal medicine; Receptor","score_opus":0.0809376976532069,"score_gpt":0.3430766452850072,"score_spread":0.2621389476318003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031439958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9079337,0.055188783,0.0011099038,0.024425795,0.0004303228,0.0025314777,0.000018350198,0.00036314558,0.007998495],"genre_scores_gemma":[0.9595048,0.025141433,0.00047622385,0.009706989,0.00048677533,0.00027436478,0.000045198965,0.00006919428,0.00429505],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99801284,0.000052270057,0.00039683035,0.00054790947,0.0004612887,0.000528852],"domain_scores_gemma":[0.9990054,0.0000794859,0.000105923136,0.00047872105,0.000101019206,0.00022944465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021192974,0.00043408995,0.00057784584,0.00018636473,0.00026394735,0.000033096196,0.00013623048,0.00016560579,0.00020767468],"category_scores_gemma":[0.000019300755,0.00031710483,0.0001931963,0.00027434633,0.00016362932,0.00009601771,0.00006344102,0.00028041805,0.0000752449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008753123,0.00844536,0.2160414,0.00044069765,0.004677537,0.00021532776,0.048972275,0.000021471766,0.5317746,0.0030624226,0.053495087,0.12410071],"study_design_scores_gemma":[0.01222523,0.0029858395,0.25653207,0.0006725601,0.000047116522,0.0004390189,0.0034865164,0.00084184046,0.007685843,0.00036451954,0.7137531,0.0009663637],"about_ca_topic_score_codex":0.0002712146,"about_ca_topic_score_gemma":0.000013513978,"teacher_disagreement_score":0.660258,"about_ca_system_score_codex":0.000059007994,"about_ca_system_score_gemma":0.00004362914,"threshold_uncertainty_score":0.9999281},"labels":[],"label_agreement":null},{"id":"W2067881291","doi":"10.1517/13543776.2013.736494","title":"Tanshinone derivatives: a patent review (January 2006 – September 2012)","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Traditional Chinese Medicine Analysis","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Neuroprotection; Prodrug; Pharmacology; In vivo; Chemistry; Kinase; Medicine; Biochemistry; Biology","score_opus":0.30002122565777783,"score_gpt":0.41776020492084603,"score_spread":0.1177389792630682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067881291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.779245e-7,0.99013895,0.00013815334,0.0010473358,0.0014640545,0.0025884386,0.00014619446,0.00017578024,0.004300246],"genre_scores_gemma":[0.000016505624,0.9801339,0.00014060255,0.0101115145,0.002017137,0.000927229,0.0036877294,0.00021546033,0.0027499148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944166,0.0006909182,0.0016342149,0.0009870209,0.0014676078,0.00080361887],"domain_scores_gemma":[0.99671,0.00028908305,0.0008192323,0.0013518223,0.00021236288,0.00061752123],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0006155348,0.0012849414,0.004252961,0.00054790964,0.00014605797,0.000023476432,0.0004438078,0.00049099687,0.0031158999],"category_scores_gemma":[0.000055516637,0.000827478,0.0017479762,0.0009689502,0.00014773762,0.00022403726,0.00008312183,0.0010517084,0.00298999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050792445,0.0010664442,0.00005932229,0.022317093,0.0024512499,0.000050121096,0.00010030065,1.12929065e-7,0.0000026580149,0.000056363595,0.081598334,0.8922472],"study_design_scores_gemma":[0.000828317,0.00029986555,0.00025866157,0.10711579,0.0014462844,0.00027470803,0.000012530508,0.000002925708,0.0000016556542,0.000025302312,0.8890791,0.00065486354],"about_ca_topic_score_codex":0.000021606122,"about_ca_topic_score_gemma":7.986745e-7,"teacher_disagreement_score":0.8915923,"about_ca_system_score_codex":0.00045776743,"about_ca_system_score_gemma":0.0003170893,"threshold_uncertainty_score":0.9999902},"labels":[],"label_agreement":null},{"id":"W2068430448","doi":"10.1517/13543770802672598","title":"Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Hepatitis C virus research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Hepatitis C virus; Medicine; Cirrhosis; Disease; Virus; Liver disease; Hepatitis C; Immunology; Intensive care medicine; Virology; Internal medicine","score_opus":0.19760100309243278,"score_gpt":0.45642617193886964,"score_spread":0.25882516884643686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068430448","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017003527,0.99470407,0.000103137405,0.00016807306,0.00065655285,0.004007013,0.000047225632,0.000015034357,0.00012884085],"genre_scores_gemma":[0.0004087009,0.9972694,0.000089503694,0.00015621471,0.00020854166,0.0015995016,0.0001972483,0.00004533578,0.000025543051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970066,0.00041924065,0.0011295273,0.00037126426,0.00072526326,0.00034813193],"domain_scores_gemma":[0.99822384,0.0005657744,0.0004620689,0.0005587828,0.00012059105,0.00006892315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046819818,0.0004069149,0.001209683,0.000333142,0.00012123741,0.000013234223,0.00023200606,0.00021256942,0.00004539544],"category_scores_gemma":[0.000056466546,0.00020797578,0.00040931124,0.000490361,0.000091152324,0.000056970734,0.000016815564,0.00019927754,0.00001277492],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001583453,0.0013841946,0.00029801964,0.0006914312,0.00024217876,0.0000018003175,0.0015775538,8.967446e-7,0.000011658541,0.000011787588,0.000046854544,0.99557525],"study_design_scores_gemma":[0.0011703918,0.0019690867,0.0006129934,0.004972572,0.000057326506,0.0000040585646,0.000037880465,0.000013788282,0.0008838941,0.000010333135,0.9900967,0.00017096587],"about_ca_topic_score_codex":0.00034325305,"about_ca_topic_score_gemma":0.0002142326,"teacher_disagreement_score":0.9954043,"about_ca_system_score_codex":0.00054865726,"about_ca_system_score_gemma":0.00047865103,"threshold_uncertainty_score":0.84810066},"labels":[],"label_agreement":null},{"id":"W2069045375","doi":"10.1517/13543776.2011.539205","title":"Signal transducer and activator of transcription 3 inhibitors: a patent review","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"STAT protein; STAT3; Regulator; In vivo; Computational biology; Small molecule; Peptidomimetic; Medicine; Cancer research; stat; Biology; Pharmacology; Signal transduction; Cell biology; Peptide; Biochemistry; Gene; Genetics","score_opus":0.18644807911706654,"score_gpt":0.39049153745478055,"score_spread":0.204043458337714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069045375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027848293,0.99636275,0.00006904539,0.00034462425,0.0012758909,0.0016352105,0.00008222274,0.00005300908,0.00014937481],"genre_scores_gemma":[0.00060003146,0.9973649,0.000053405874,0.00080821366,0.00048303822,0.00026653524,0.0002768239,0.000092183036,0.000054877895],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975538,0.00018594367,0.0010035394,0.0005330544,0.00045519735,0.00026845356],"domain_scores_gemma":[0.998721,0.00008942148,0.000441088,0.00043552287,0.0001190691,0.00019389157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023569247,0.0005429828,0.0019118539,0.00024817124,0.00007258456,0.000016687327,0.00012940257,0.00040174805,0.0005913718],"category_scores_gemma":[0.000018091134,0.0003759571,0.00084611395,0.00024975833,0.00008551126,0.00008553411,0.000014856494,0.0008085134,0.000032709006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008406032,0.0004761054,0.0000017801271,0.013122428,0.00029147082,0.0000034200905,0.00016510858,1.870914e-8,0.007963678,0.00002778634,0.00047667127,0.9773875],"study_design_scores_gemma":[0.00065866415,0.0006695918,0.0000070131905,0.12196334,0.00026728606,0.00010757798,0.0000136007075,0.0000043070527,0.0018643632,0.000006934092,0.87415487,0.00028244464],"about_ca_topic_score_codex":0.000023764487,"about_ca_topic_score_gemma":3.1801903e-7,"teacher_disagreement_score":0.977105,"about_ca_system_score_codex":0.000083446146,"about_ca_system_score_gemma":0.00017948156,"threshold_uncertainty_score":0.9998692},"labels":[],"label_agreement":null},{"id":"W2084903264","doi":"10.1517/13543776.17.4.371","title":"Metabotropic glutamate receptor 5 modulators and their potential therapeutic applications","year":2007,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Neuroscience and Neuropharmacology Research","field":"Neuroscience","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"AstraZeneca","keywords":"Metabotropic glutamate receptor; Metabotropic glutamate receptor 5; Neuroscience; Metabotropic receptor; Metabotropic glutamate receptor 2; Glutamate receptor; Receptor; Class C GPCR; Metabotropic glutamate receptor 1; Metabotropic glutamate receptor 7; Pharmacology; Biology; Biochemistry","score_opus":0.08032992125195253,"score_gpt":0.3618215717416292,"score_spread":0.28149165048967667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084903264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782436,0.004108701,0.009037756,0.0016206381,0.00411931,0.0018640487,0.000038140748,0.00041201388,0.00055579556],"genre_scores_gemma":[0.98668784,0.0053721215,0.00002056854,0.0073357495,0.0002513493,0.00012771528,0.0000018124565,0.000048752427,0.00015410242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99726325,0.00032523496,0.000331608,0.0008662208,0.00048289646,0.00073081255],"domain_scores_gemma":[0.9988783,0.00026148945,0.00011473923,0.00044109006,0.000042430504,0.0002619569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003420001,0.00031920677,0.0002508325,0.00026063836,0.0005795848,0.00009399491,0.00055275194,0.000109686516,0.00011737258],"category_scores_gemma":[0.000023977012,0.000237888,0.0001028186,0.00053250307,0.0004080997,0.00021616099,0.00012372289,0.00035486103,0.00022531797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001954792,0.00026900292,0.00019795286,0.0000042925303,0.000011982282,0.000007090801,0.00018687552,0.0000070193796,0.92570233,0.0012914343,0.00003636576,0.0720902],"study_design_scores_gemma":[0.0010041328,0.0003921392,0.004035633,0.000008926981,0.0000032612481,0.00004288558,0.00007901691,0.000797407,0.9275649,0.0010535802,0.06470197,0.00031615567],"about_ca_topic_score_codex":0.000003882714,"about_ca_topic_score_gemma":1.1582591e-7,"teacher_disagreement_score":0.07177404,"about_ca_system_score_codex":0.000042663993,"about_ca_system_score_gemma":0.00003509336,"threshold_uncertainty_score":0.9700791},"labels":[],"label_agreement":null},{"id":"W2102449842","doi":"10.1517/13543776.10.5.675","title":"Tyrosine phosphatases: cellular functions and therapeutic potential","year":2000,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Protein tyrosine phosphatase; Tyrosine; Tyrosine phosphorylation; Receptor tyrosine kinase; Phosphorylation; Protein phosphorylation; Biochemistry; Tyrosine kinase; SH2 domain; Platelet-derived growth factor receptor; Cell biology; Proto-oncogene tyrosine-protein kinase Src; Phosphatase; Chemistry; Biology; Signal transduction; Protein kinase A; Receptor; Growth factor","score_opus":0.0197475529811363,"score_gpt":0.2656236591770438,"score_spread":0.2458761061959075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102449842","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25922275,0.72709364,0.0056200125,0.0017685682,0.0026359034,0.001733085,0.000602725,0.00024169839,0.0010816455],"genre_scores_gemma":[0.98184687,0.012734006,0.0001273021,0.0028588779,0.00042969128,0.000118917196,0.00088399625,0.00006150887,0.0009388096],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983837,0.00010730903,0.00026408304,0.0006008878,0.0002534885,0.00039051689],"domain_scores_gemma":[0.9991513,0.000011575694,0.000071175855,0.0005711845,0.00004497369,0.00014979605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010977493,0.00032622495,0.0001993387,0.00005068975,0.00024281601,0.0000607092,0.00023712621,0.0001672945,0.0006426517],"category_scores_gemma":[0.0000090318645,0.00029099354,0.00010626374,0.00011162254,0.00014066395,0.000010524926,0.000059045247,0.00011844162,0.0001873696],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015406965,0.00073179166,0.00059091486,0.000016991822,0.0003520703,0.000012632974,0.00009490026,0.00016972458,0.46911356,0.00088652404,0.00642608,0.5200641],"study_design_scores_gemma":[0.0021010574,0.0010646911,0.0023833306,0.000045751072,0.00001500364,0.000032251515,0.000063860316,0.00022972535,0.5757854,0.00026878124,0.41748026,0.0005299022],"about_ca_topic_score_codex":0.000049068538,"about_ca_topic_score_gemma":8.8051064e-7,"teacher_disagreement_score":0.7226241,"about_ca_system_score_codex":0.00001985165,"about_ca_system_score_gemma":0.000036293306,"threshold_uncertainty_score":0.9999542},"labels":[],"label_agreement":null},{"id":"W2112661022","doi":"10.1517/13543776.2014.1000303","title":"Therapeutic uses of furin and its inhibitors: a patent review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cellular transport and secretion","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Furin; Context (archaeology); Clinical trial; Medicine; Drug discovery; Computational biology; Pharmacology; Bioinformatics; Biology; Biochemistry; Enzyme","score_opus":0.17319279252688577,"score_gpt":0.363310240735042,"score_spread":0.1901174482081562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112661022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004201531,0.9979265,0.0000793257,0.00004885538,0.0006445332,0.0011064095,0.00005495334,0.000018081255,0.00007932699],"genre_scores_gemma":[0.0006137735,0.9951499,0.000009684973,0.0004373827,0.0002911233,0.000161278,0.003138701,0.00008395489,0.000114162714],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976779,0.00030279878,0.0007463857,0.0006162867,0.00036867187,0.00028794826],"domain_scores_gemma":[0.99876475,0.000016024875,0.00042196835,0.0005189592,0.00013238398,0.00014589826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036377215,0.00054441625,0.0011999409,0.00010080526,0.00004820966,0.000014340297,0.00028035065,0.00042784345,0.000036685666],"category_scores_gemma":[0.000012478446,0.0004089216,0.00044441991,0.00015705811,0.000052462477,0.000005888189,0.00006653344,0.00019113113,0.000025616204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007305743,0.00026602866,0.0000180662,0.010282968,0.0004908785,0.000003574518,0.00008133581,1.8975787e-7,0.0028032337,0.00007067435,0.00029458982,0.98561543],"study_design_scores_gemma":[0.00040618403,0.00049073057,0.0000071403783,0.017066116,0.000106323074,0.000021296071,0.00001076063,0.00000272226,0.00062715495,0.000015494774,0.9808302,0.00041590526],"about_ca_topic_score_codex":0.0000072742628,"about_ca_topic_score_gemma":6.419124e-7,"teacher_disagreement_score":0.9851995,"about_ca_system_score_codex":0.00003381392,"about_ca_system_score_gemma":0.00015412901,"threshold_uncertainty_score":0.99983627},"labels":[],"label_agreement":null},{"id":"W2117496910","doi":"10.1517/13543776.18.9.975","title":"Structural biology in the battle against BCR-Abl","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Vertex Pharmaceuticals; Bristol-Myers Squibb; Boehringer Ingelheim","keywords":"Imatinib; Chronic myelogenous leukemia; Tyrosine kinase; Drug resistance; ABL; Tyrosine-kinase inhibitor; Drug; Cancer research; Pharmacology; Medicine; Leukemia; Biology; Cancer; Immunology; Myeloid leukemia; Internal medicine; Receptor; Genetics","score_opus":0.10270415001056933,"score_gpt":0.34708296736244654,"score_spread":0.24437881735187722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117496910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877893,0.005492812,0.000017565788,0.0020089748,0.0017243513,0.0005714195,0.000009784949,0.000071042115,0.0023147797],"genre_scores_gemma":[0.9910434,0.0031704248,0.00008320613,0.0050452542,0.000281603,0.00008023951,0.00014244937,0.000028095097,0.00012535125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985106,0.00017692991,0.00028423057,0.00035291864,0.0002844507,0.00039087795],"domain_scores_gemma":[0.99911374,0.00018775855,0.000072727744,0.0005187786,0.000028466733,0.000078520156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112148315,0.00024181497,0.00029298387,0.000114361836,0.0001355406,0.000007944217,0.00022332538,0.00013611202,0.00018896893],"category_scores_gemma":[0.000041052786,0.00014422569,0.00010525935,0.00019560447,0.00013059087,0.00004879684,0.000029176183,0.00025668534,0.00020430941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027236848,0.0026785864,0.475282,0.000061830935,0.0010462083,0.00069583085,0.02863349,0.000097896154,0.030939689,0.002113552,0.010173589,0.44555363],"study_design_scores_gemma":[0.02385741,0.0023422623,0.7893287,0.00031176914,0.000016994802,0.000742137,0.0010914505,0.002141274,0.006179887,0.00047256876,0.1727409,0.00077463605],"about_ca_topic_score_codex":0.00012669765,"about_ca_topic_score_gemma":0.0000023484747,"teacher_disagreement_score":0.444779,"about_ca_system_score_codex":0.00039383597,"about_ca_system_score_gemma":0.00012410812,"threshold_uncertainty_score":0.5881353},"labels":[],"label_agreement":null},{"id":"W2124374772","doi":"10.1517/13543770802557740","title":"Non-antibiotic strategies for the prevention/treatment of<i>Clostridium difficile</i>infection","year":2008,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences","funders":"","keywords":"Clostridium difficile; Metronidazole; Medicine; Antibiotics; Vancomycin; Intensive care medicine; Enterocolitis; Diarrhea; Disease; Internal medicine; Microbiology; Bacteria; Biology; Staphylococcus aureus","score_opus":0.12955088693887748,"score_gpt":0.37628800678545005,"score_spread":0.24673711984657257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124374772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98183596,0.008288679,0.0021364745,0.0016271789,0.0015959528,0.0032135288,0.000042381904,0.00011287724,0.0011469853],"genre_scores_gemma":[0.97449243,0.023745876,0.00006720344,0.00016190697,0.0005491729,0.00020556773,0.00008453245,0.000049479768,0.0006438356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980417,0.000058427097,0.00047379607,0.000418456,0.00056067575,0.00044693617],"domain_scores_gemma":[0.99866956,0.00021950384,0.00016496236,0.0005998908,0.00021734215,0.00012874402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013150225,0.00032442927,0.00045608944,0.0001563691,0.0003783441,0.000021741092,0.00014517864,0.00014928808,0.000099020326],"category_scores_gemma":[0.000022414191,0.0002047597,0.0004501305,0.00029520874,0.00019068421,0.00007522066,0.00002539639,0.00013746035,0.00005715584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011849178,0.021560617,0.019021615,0.00045820462,0.004188228,0.00006493263,0.006184689,0.00070167007,0.6920255,0.0017728268,0.00938486,0.23278771],"study_design_scores_gemma":[0.008283737,0.010862132,0.017390965,0.0002718356,0.000090477806,0.00012798097,0.0007913381,0.002280868,0.90614855,0.000114280534,0.053236317,0.0004015221],"about_ca_topic_score_codex":0.00023536981,"about_ca_topic_score_gemma":0.0000030778365,"teacher_disagreement_score":0.2323862,"about_ca_system_score_codex":0.00023125237,"about_ca_system_score_gemma":0.00035696896,"threshold_uncertainty_score":0.8349858},"labels":[],"label_agreement":null},{"id":"W2137798595","doi":"10.1517/13543771003702432","title":"Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase","year":2010,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Steatosis; Pharmacology; Medicine; Disease; Metabolic syndrome; Diabetes mellitus; Chemistry; Bioinformatics; Biochemistry; Biology; Internal medicine; Endocrinology","score_opus":0.0652826197250013,"score_gpt":0.3566787178923051,"score_spread":0.29139609816730383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137798595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826444,0.0007842003,0.00018538855,0.0024716777,0.0069115427,0.0007107829,0.000023824086,0.00014145048,0.000506702],"genre_scores_gemma":[0.99695,0.00014678261,0.0010458392,0.0013840396,0.00029529008,0.000037401922,0.00006632941,0.000048606846,0.000025743062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765825,0.00014222569,0.0004983446,0.00037900492,0.0007395954,0.00058254966],"domain_scores_gemma":[0.9986505,0.00016862358,0.0001914768,0.00056775875,0.000114228664,0.000307394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033312602,0.00027455465,0.00035830992,0.00024424444,0.00023971821,0.000054938173,0.0003730139,0.0002101697,0.0001349348],"category_scores_gemma":[0.00008549234,0.00022629574,0.00014170614,0.00026699543,0.00023129178,0.00017294158,0.00004848406,0.0005992713,0.00020547153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009002392,0.00089106715,0.0013502416,0.00006111204,0.00005634078,0.0000028086624,0.0013811686,0.0000055015526,0.97592986,0.00026781668,0.0007209991,0.018432867],"study_design_scores_gemma":[0.005991299,0.0016918599,0.030849023,0.00050781836,0.00000704804,0.000048327292,0.00047568587,0.0015094732,0.9411133,0.0006389455,0.01657925,0.0005879476],"about_ca_topic_score_codex":0.0005679037,"about_ca_topic_score_gemma":0.00002715823,"teacher_disagreement_score":0.034816515,"about_ca_system_score_codex":0.000088275265,"about_ca_system_score_gemma":0.00007587422,"threshold_uncertainty_score":0.9228072},"labels":[],"label_agreement":null},{"id":"W2156817850","doi":"10.1517/13543776.16.7.977","title":"TRPV1 antagonists: a survey of the patent literature","year":2006,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"TRPV1; Pharmacology; Medicine; Clinical trial; Computational biology; Business; Biology; Receptor; Internal medicine; Transient receptor potential channel","score_opus":0.12225705841958406,"score_gpt":0.3083448457455742,"score_spread":0.18608778732599013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156817850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96659744,0.0077267485,0.00019317734,0.0026680492,0.019172821,0.0012127132,0.00035048672,0.0001854125,0.0018931632],"genre_scores_gemma":[0.99657065,0.001191929,0.0000069374732,0.0014363184,0.00017565083,0.000020852558,0.000024737774,0.000025881625,0.0005470462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981031,0.00046164854,0.00031395725,0.0003667472,0.00047037666,0.0002841806],"domain_scores_gemma":[0.99927914,0.00011499556,0.00017382123,0.00031723114,0.000069510046,0.000045308836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018686503,0.00020702371,0.00019495813,0.000065260814,0.00019825662,0.00005085621,0.0004218758,0.0001140005,0.000060650924],"category_scores_gemma":[0.000045863875,0.00011567831,0.00013784593,0.00040103303,0.00012468392,0.000071546994,0.00005914019,0.00017490915,0.00003445338],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051849027,0.0019473649,0.011437732,0.000035175588,0.000035620804,0.00000797277,0.0023582212,0.0002162471,0.9503678,0.0038492586,0.008774337,0.02045176],"study_design_scores_gemma":[0.0011108102,0.00018455979,0.077846095,0.00020674308,0.0000013392715,0.000012332336,0.000035678197,0.0004000927,0.8935774,0.0006345623,0.025701668,0.00028871658],"about_ca_topic_score_codex":0.00028250754,"about_ca_topic_score_gemma":0.0000033508009,"teacher_disagreement_score":0.066408366,"about_ca_system_score_codex":0.00004014384,"about_ca_system_score_gemma":0.000029222085,"threshold_uncertainty_score":0.47172245},"labels":[],"label_agreement":null},{"id":"W2162925667","doi":"10.1517/13543776.13.7.979","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Epilepsy; Drug; Anticonvulsant; Anticonvulsant drugs; Medicine; Action (physics); Pharmacology; Psychiatry","score_opus":0.10701063613566658,"score_gpt":0.3617737780236091,"score_spread":0.2547631418879425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162925667","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.372556,0.5399538,0.0011915365,0.0445278,0.0060398392,0.010950468,0.0002901101,0.0006800025,0.023810381],"genre_scores_gemma":[0.86785537,0.1103427,0.000495845,0.018093761,0.0002432845,0.0005523378,0.00011508188,0.000074843265,0.0022267834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99736845,0.00034967638,0.0003152089,0.0006147772,0.0007761105,0.00057574234],"domain_scores_gemma":[0.9983095,0.0001121774,0.00008326729,0.00079374417,0.00009814869,0.0006031862],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028471474,0.00034089028,0.00053329807,0.00011665354,0.00012754444,0.000022897348,0.00015720037,0.00008358825,0.0021801444],"category_scores_gemma":[0.00009491436,0.00024715665,0.00021705062,0.00025819405,0.00003968719,0.00007209103,0.000037028494,0.0002625124,0.0025659741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031158451,0.009103315,0.0815145,0.00028935046,0.001702699,0.00026224562,0.0015492748,0.0000050134777,0.020844629,0.0004110209,0.22294319,0.6582589],"study_design_scores_gemma":[0.0052680387,0.0018401351,0.097589776,0.0026987228,0.000035690085,0.000021574548,0.000096681,0.000041058505,0.03816998,0.0002000746,0.85350806,0.00053018716],"about_ca_topic_score_codex":0.00033751593,"about_ca_topic_score_gemma":0.000004154509,"teacher_disagreement_score":0.65772873,"about_ca_system_score_codex":0.00024378719,"about_ca_system_score_gemma":0.00009447665,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2173701041","doi":"10.1517/13543776.2016.1115836","title":"Transglutaminase inhibitors: a patent review","year":2015,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Blood properties and coagulation","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Tissue transglutaminase; Deamidation; Glutamine; Enzyme; Disease; GTP'; Cancer; Biochemistry; Pharmacology; Chemistry; Medicine; Biology; Cancer research; Amino acid; Internal medicine","score_opus":0.34857619274033974,"score_gpt":0.4178338653797347,"score_spread":0.06925767263939497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173701041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.804944e-7,0.9941864,0.00001678561,0.00067256327,0.0015658962,0.0028341243,0.00002613774,0.00013863426,0.000558686],"genre_scores_gemma":[0.00001926778,0.9932514,0.000034785535,0.0039395047,0.00079622376,0.00063150615,0.0006607588,0.00014787736,0.00051867607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966414,0.00035722286,0.0010449146,0.00068785466,0.00083256426,0.00043603915],"domain_scores_gemma":[0.99822897,0.000034171182,0.0003743994,0.00085114496,0.00017047755,0.00034081988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043008255,0.0007324339,0.0024517819,0.00018321171,0.00008165344,0.00002841825,0.00023639841,0.00043208574,0.00023463472],"category_scores_gemma":[0.00002259805,0.00046630256,0.0008758274,0.00040211773,0.000054161166,0.00007241215,0.00004385913,0.0005061894,0.0006464455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000634521,0.0003815607,0.0000016299845,0.016542714,0.00030740528,0.000015854112,0.00009522427,5.3641074e-8,0.0000011493113,0.00001492638,0.0066415304,0.9759345],"study_design_scores_gemma":[0.00083951524,0.0007254511,0.000002767184,0.15225914,0.00033472618,0.00010733899,0.000014835967,0.000007956189,0.000005213516,0.000010915448,0.84527934,0.00041281545],"about_ca_topic_score_codex":0.000021141657,"about_ca_topic_score_gemma":1.4965205e-7,"teacher_disagreement_score":0.9755217,"about_ca_system_score_codex":0.0002842532,"about_ca_system_score_gemma":0.00036753688,"threshold_uncertainty_score":0.99977887},"labels":[],"label_agreement":null},{"id":"W2179086760","doi":"10.1517/13543776.2016.1118062","title":"Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Chemistry; Kinase; Pharmacology; Biochemistry; Receptor; Nerve growth factor; Biology","score_opus":0.4187022352765148,"score_gpt":0.41256677857361945,"score_spread":0.006135456702895337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179086760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90599,0.0024274725,0.07164816,0.0037740462,0.00903641,0.004867904,0.00023224019,0.0002934068,0.0017303427],"genre_scores_gemma":[0.9974185,0.000027168122,0.00032026332,0.0015585155,0.00024211731,0.00028627896,0.0000680136,0.000026736594,0.000052384024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763805,0.00034449555,0.00033507516,0.0003900023,0.0010794954,0.00021286051],"domain_scores_gemma":[0.9989207,0.000103528604,0.00021839108,0.00028562525,0.00037451118,0.00009728754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012171108,0.00017763444,0.00017629002,0.00014703134,0.00011314456,0.000029935285,0.00013375524,0.00011780965,0.000026291753],"category_scores_gemma":[0.00024210899,0.00014550981,0.00010491387,0.00020305178,0.0000674627,0.00018870433,0.000013986318,0.000060953556,0.000023629598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004427122,0.00071716175,0.000024208863,0.0000086592,0.000012251718,1.8318933e-7,0.00033688705,0.001737269,0.9594283,0.0021000244,0.0006572709,0.034535088],"study_design_scores_gemma":[0.004444592,0.00073599775,0.00013398023,0.00007646618,0.000011292552,0.000002305013,0.000045775094,0.059759803,0.92917746,0.0016147483,0.0038225998,0.00017499574],"about_ca_topic_score_codex":0.000011766727,"about_ca_topic_score_gemma":0.0000010962295,"teacher_disagreement_score":0.0914285,"about_ca_system_score_codex":0.00014378682,"about_ca_system_score_gemma":0.00018695068,"threshold_uncertainty_score":0.59337175},"labels":[],"label_agreement":null},{"id":"W2466927139","doi":"10.1080/13543776.2016.1206080","title":"Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Fondation Leducq","keywords":"PCSK9; Alirocumab; Evolocumab; Kexin; Proprotein convertase; Dyslipidemia; Medicine; Pharmacology; Monoclonal antibody; Cholesterol; LDL receptor; Antibody; Internal medicine; Immunology; Lipoprotein; Disease","score_opus":0.08188793832644997,"score_gpt":0.36030734811684423,"score_spread":0.27841940979039426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466927139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003268545,0.98585415,0.00002030571,0.0027452493,0.0017437476,0.009362099,0.000102148064,0.00009113614,0.00004845729],"genre_scores_gemma":[0.0001224274,0.99210286,0.00003511239,0.003765591,0.0018234458,0.0011512572,0.0006651643,0.00018282153,0.00015132272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99286693,0.0024154591,0.0017286312,0.001081745,0.0012632075,0.00064401975],"domain_scores_gemma":[0.9957718,0.00010288499,0.0010936905,0.002301323,0.00029591442,0.0004343719],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027939011,0.0010435372,0.004231293,0.00022396963,0.00018409322,0.00003248457,0.000493785,0.00070151326,0.00051484065],"category_scores_gemma":[0.000035357556,0.00046853017,0.0013920453,0.00027337065,0.00038943245,0.00012959955,0.00010539697,0.0007916604,0.00011821613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005709112,0.0002853962,0.000008512243,0.008240288,0.0010860243,0.000009889593,0.00013853189,8.606741e-9,0.000009612322,0.00014756642,0.0027981603,0.9867051],"study_design_scores_gemma":[0.0052301884,0.0007805369,0.000033385284,0.051469777,0.00024564555,0.000087908775,0.000044130033,0.0000028221186,0.00007980965,0.00004589388,0.9414789,0.0005010023],"about_ca_topic_score_codex":0.00014219143,"about_ca_topic_score_gemma":0.0000017940596,"teacher_disagreement_score":0.9862041,"about_ca_system_score_codex":0.00020271055,"about_ca_system_score_gemma":0.0005779772,"threshold_uncertainty_score":0.99977666},"labels":[],"label_agreement":null},{"id":"W2500524559","doi":"10.1080/13543776.2016.1216545","title":"Therapeutic significance of quinolines: a patent review (2013-2015)","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Synthesis and Reactivity of Heterocycles","field":"Chemistry","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Quinoline; Pharmacophore; Antimicrobial; Broad spectrum; Combinatorial chemistry; Chemistry; Pharmacology; Medicine; Computational biology; Biology; Bioinformatics; Organic chemistry","score_opus":0.17850585215273945,"score_gpt":0.3792114764262831,"score_spread":0.20070562427354366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500524559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021587566,0.9965452,0.00005163405,0.00043135518,0.0010330153,0.00085833616,0.00016157022,0.00013394949,0.0007827963],"genre_scores_gemma":[0.00016141501,0.9972252,0.000022607379,0.00056433375,0.00058006326,0.0006853907,0.00011388707,0.00020826964,0.00043882657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99534863,0.000364428,0.0015875723,0.0010931062,0.00089522474,0.0007110466],"domain_scores_gemma":[0.9958095,0.0006145169,0.0015902219,0.0016547856,0.00012501911,0.00020595071],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003643557,0.001145327,0.003348704,0.00019697325,0.00012177951,0.000033333807,0.0011349663,0.0006517008,0.0016445755],"category_scores_gemma":[0.00004269948,0.00068679743,0.0015586608,0.00017554527,0.00021312,0.00011264732,0.000115923256,0.00045421824,0.0005653582],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000335803,0.00046603795,0.000002720958,0.02083509,0.00072201603,0.000003480072,0.000046071495,4.4170633e-8,0.0005644145,0.000029152376,0.0012015731,0.9760958],"study_design_scores_gemma":[0.00035085165,0.00007257327,0.0000023805753,0.16771941,0.00011258987,0.0000223239,0.000016400074,0.0000016030807,0.00071956654,0.000055907854,0.830233,0.00069339207],"about_ca_topic_score_codex":0.000052796022,"about_ca_topic_score_gemma":6.5123004e-7,"teacher_disagreement_score":0.9754024,"about_ca_system_score_codex":0.00024161328,"about_ca_system_score_gemma":0.00020529822,"threshold_uncertainty_score":0.9995583},"labels":[],"label_agreement":null},{"id":"W2590195415","doi":"10.1080/13543776.2017.1297796","title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 –<i>Part I</i>","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Kinase; Context (archaeology); Biology; Receptor; Neurotrophin; Cell biology; Biochemistry","score_opus":0.40899024812389073,"score_gpt":0.4358830275645397,"score_spread":0.026892779440648995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590195415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002285163,0.97964656,0.000065622684,0.0006390535,0.014507869,0.0042780996,0.0005413975,0.00019244492,0.00012668216],"genre_scores_gemma":[0.000005058435,0.9865326,0.000072391,0.0036886067,0.0023933952,0.0017417547,0.0022954366,0.00020021995,0.0030705195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941191,0.00143791,0.0014012061,0.0016319163,0.00067215506,0.0007376916],"domain_scores_gemma":[0.996066,0.00014444812,0.0014403791,0.00187659,0.00013429884,0.00033830697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007080833,0.0010392976,0.0019854729,0.00022636079,0.00082397525,0.00024660552,0.0012823931,0.00057658163,0.00033166434],"category_scores_gemma":[0.00014551329,0.00071530923,0.0009769014,0.00022740554,0.00019168468,0.0004891847,0.000111223235,0.00048442755,0.00072744477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007179845,0.0004830359,1.13418245e-7,0.0022633797,0.00005177487,0.00000391766,0.000024954774,1.5676093e-7,0.0018565363,0.00019015723,0.08989716,0.905157],"study_design_scores_gemma":[0.00064934406,0.0007174005,1.4249817e-7,0.035818104,0.000072273215,0.00001663817,0.0000027919593,0.000011094882,0.009035669,0.000038539052,0.9527927,0.0008452722],"about_ca_topic_score_codex":0.000015494868,"about_ca_topic_score_gemma":6.269771e-7,"teacher_disagreement_score":0.9043117,"about_ca_system_score_codex":0.00023107462,"about_ca_system_score_gemma":0.000295036,"threshold_uncertainty_score":0.9995298},"labels":[],"label_agreement":null},{"id":"W2590797524","doi":"10.1080/13543776.2017.1296950","title":"Patent disclosure requirements for therapeutic antibody patents","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Antibody; Pharmacology; Medicine; Immunology","score_opus":0.6197336892953145,"score_gpt":0.48238085560467564,"score_spread":0.13735283369063883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590797524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000051169905,0.98292524,0.00058930635,0.0006519758,0.0072510946,0.0027831076,0.0020755837,0.00010030444,0.0036182478],"genre_scores_gemma":[0.00083029055,0.9915394,0.00005447129,0.0026717535,0.0011495723,0.0010927314,0.0013555785,0.00032210903,0.0009841014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441004,0.00013353545,0.0023056965,0.001689679,0.0001638075,0.0012972371],"domain_scores_gemma":[0.9951449,0.0001802049,0.0023257844,0.0018608046,0.000065744665,0.00042256434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009184917,0.0012520087,0.0034055868,0.00055304385,0.0006277544,0.00044132688,0.0018363681,0.0007814199,0.00040062162],"category_scores_gemma":[0.0000575287,0.0011350765,0.0017445757,0.00016275383,0.00017011639,0.0003283029,0.00023831816,0.0006014791,0.0023635593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090607246,0.00066950574,0.00018393873,0.0015963544,0.0016298454,0.000004093841,0.00014737326,0.0000014809546,0.0000019003007,0.026272174,0.0017230725,0.9676797],"study_design_scores_gemma":[0.0017860071,0.000328142,0.00010965861,0.0023136893,0.000057207006,0.000006558915,0.0000072163743,0.00023863195,0.0000038103813,0.010600681,0.9832892,0.0012592106],"about_ca_topic_score_codex":0.000060597722,"about_ca_topic_score_gemma":0.0000011546329,"teacher_disagreement_score":0.98156613,"about_ca_system_score_codex":0.0005254365,"about_ca_system_score_gemma":0.00013296223,"threshold_uncertainty_score":0.9991099},"labels":[],"label_agreement":null},{"id":"W2762459231","doi":"10.1080/13543776.2018.1388780","title":"Bill C-30: who wins and who loses in Canada’s pharmaceutical patent battles?","year":2017,"lang":"en","type":"editorial","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Business; Patent analysis; Patent troll; Patent law; Law; Political science; Computer science; Intellectual property","score_opus":0.14818294676430427,"score_gpt":0.340395631864411,"score_spread":0.19221268510010675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762459231","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029532413,0.0511818,0.000027328722,0.008973849,0.91820467,0.0011719791,0.0044925166,0.00006134505,0.012933256],"genre_scores_gemma":[0.2103523,0.36314613,0.00003080716,0.016584542,0.40544635,0.00040165609,0.00081938243,0.0005129132,0.0027059314],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962104,0.000086010485,0.0012385906,0.0012533688,0.0002197559,0.000991851],"domain_scores_gemma":[0.9974678,0.00040028512,0.00072071876,0.00086819404,0.000054558677,0.0004884249],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054935156,0.00073313003,0.0014452694,0.00035743456,0.0002475207,0.00027234983,0.0009233255,0.00088205305,0.00067152665],"category_scores_gemma":[0.00021061944,0.00069830916,0.0001906224,0.00008403948,0.00017652047,0.00021164463,0.00026044212,0.0015148621,0.00035966004],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002362267,0.00026977685,0.006360121,0.00009764858,0.00034396723,0.00002989989,0.00038900768,0.000022622351,0.000004368391,0.0037209417,0.96681917,0.021706257],"study_design_scores_gemma":[0.002473201,0.00011182373,0.0039258157,0.0002590413,0.0000052247497,0.0000016960946,0.000023778,0.0022276633,0.00003641045,0.0023628965,0.98769283,0.0008795951],"about_ca_topic_score_codex":0.35204232,"about_ca_topic_score_gemma":0.02710923,"teacher_disagreement_score":0.5127583,"about_ca_system_score_codex":0.0014072108,"about_ca_system_score_gemma":0.0008904919,"threshold_uncertainty_score":0.9995468},"labels":[],"label_agreement":null},{"id":"W3081954160","doi":"10.1080/13543776.2020.1817390","title":"Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature","year":2020,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Liver physiology and pathology","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Proteases; TMPRSS2; Respiratory tract; Transmembrane protein; Serine; Biology; Medicine; Pharmacology; Respiratory system; Immunology; Enzyme; Receptor; Coronavirus disease 2019 (COVID-19); Biochemistry; Pathology; Disease; Internal medicine; Infectious disease (medical specialty)","score_opus":0.15084764434932343,"score_gpt":0.3814635435339384,"score_spread":0.23061589918461498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081954160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013457406,0.9949325,1.8813859e-7,0.0002466268,0.0003467814,0.0028719306,0.00023117867,0.0000064567794,0.000018594697],"genre_scores_gemma":[0.012360104,0.98654085,0.000004322924,0.00056995096,0.000109647226,0.0002130852,0.0001656229,0.000026391497,0.0000100127945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713415,0.0010586298,0.0010319888,0.00030360126,0.00032035407,0.0001513048],"domain_scores_gemma":[0.9982332,0.00017263893,0.00077819946,0.00065557886,0.000112838985,0.00004753468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016184838,0.00037091467,0.0021454324,0.000110307876,0.000028356062,0.000001070474,0.00029348745,0.00022886251,0.000042001193],"category_scores_gemma":[0.000041872267,0.00016439876,0.00081482786,0.0005579913,0.00019735257,0.000023476687,0.00002384516,0.00023499396,0.0000012806754],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011067642,0.008025639,0.00066268013,0.121206224,0.000921697,0.00003361584,0.004097023,6.699681e-7,0.00091616274,0.000064128144,0.0001509624,0.8628144],"study_design_scores_gemma":[0.0022674424,0.010188011,0.00416334,0.25077438,0.0007229642,0.00003902037,0.00006705682,9.362129e-7,0.0012553487,0.000030369207,0.73024654,0.00024458248],"about_ca_topic_score_codex":0.00001126739,"about_ca_topic_score_gemma":1.3035411e-7,"teacher_disagreement_score":0.86256987,"about_ca_system_score_codex":0.00004082172,"about_ca_system_score_gemma":0.00027584416,"threshold_uncertainty_score":0.6703987},"labels":[],"label_agreement":null},{"id":"W4231919180","doi":"10.1080/13543776.2017.1297797","title":"Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – <i>Part II</i>","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Signaling Pathways in Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trk receptor; Tropomyosin receptor kinase A; Drug development; Medicine; Pharmacology; Cancer research; Internal medicine; Drug; Receptor; Neurotrophin","score_opus":0.22703980821993844,"score_gpt":0.40521853145020315,"score_spread":0.1781787232302647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231919180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001254613,0.98927486,0.000055020813,0.00020871065,0.0061978376,0.00314669,0.0009566157,0.000076956836,0.00007074735],"genre_scores_gemma":[0.000012887929,0.97462523,0.0001511017,0.0022711067,0.002494554,0.001829638,0.016896175,0.00026085068,0.00145847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99566907,0.00057989854,0.0011068567,0.0014956229,0.0004425175,0.0007060456],"domain_scores_gemma":[0.99577737,0.000029012685,0.001070373,0.002467809,0.00023243275,0.0004229886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000603162,0.0010509554,0.0016394325,0.00010111147,0.00049547636,0.000093331,0.0013104224,0.0007749268,0.00017807918],"category_scores_gemma":[0.000125062,0.00082814984,0.0011609008,0.00010151896,0.00015713659,0.000017618479,0.00026100685,0.00029445655,0.0001578753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015525286,0.00060520164,0.000001018756,0.0023930408,0.00038086652,0.0000026431346,0.000015659809,2.0177424e-7,0.0011054558,0.000011916616,0.2189704,0.77635837],"study_design_scores_gemma":[0.0009516427,0.001219752,3.2418606e-7,0.02803245,0.00014582094,0.000008838409,0.000004758779,0.0000016657386,0.0033659898,0.000012916547,0.9652947,0.00096110994],"about_ca_topic_score_codex":0.000013680623,"about_ca_topic_score_gemma":5.4084694e-7,"teacher_disagreement_score":0.77539724,"about_ca_system_score_codex":0.00012115767,"about_ca_system_score_gemma":0.00049726095,"threshold_uncertainty_score":0.99941695},"labels":[],"label_agreement":null},{"id":"W4235008009","doi":"10.1517/eotp.13.10.1491.22914","title":"Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Menstrual Health and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Premenstrual dysphoric disorder; Etiology; Serotonergic; Medicine; Psychiatry; Physiology; Psychology; Hormone; Internal medicine; Serotonin; Menstrual cycle; Receptor","score_opus":0.058909408830325,"score_gpt":0.33067366242737745,"score_spread":0.2717642535970525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235008009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69888127,0.2912391,0.0003340383,0.0032623946,0.0025802618,0.0032641885,0.000032694366,0.00008642855,0.0003196091],"genre_scores_gemma":[0.8922466,0.10633069,0.0002212799,0.0003289326,0.00015751319,0.00038475826,0.00001339304,0.000042821026,0.00027402933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982147,0.00013623305,0.00039257205,0.00049662776,0.0003412687,0.00041858232],"domain_scores_gemma":[0.9990354,0.00014506205,0.00014636668,0.00034494625,0.000103837345,0.00022438295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014179293,0.00034480155,0.00047710442,0.0001280038,0.0003756307,0.000017275743,0.00006902282,0.00015093762,0.000051972485],"category_scores_gemma":[0.00001980183,0.00021726298,0.00013247419,0.0001881303,0.00014959794,0.000059075308,0.000009805005,0.000120623365,0.0000020126329],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002390144,0.0041177357,0.037198614,0.00018191441,0.0010230578,0.000004993437,0.017599776,0.0000022405889,0.00051896693,0.0028188678,0.00015784697,0.9339858],"study_design_scores_gemma":[0.01717653,0.020089844,0.2898741,0.00015282907,0.00021651533,0.0003135153,0.020964336,0.00042262665,0.00042747866,0.00078219455,0.6489163,0.0006637194],"about_ca_topic_score_codex":0.00019231276,"about_ca_topic_score_gemma":0.0000053400768,"teacher_disagreement_score":0.93332213,"about_ca_system_score_codex":0.00032838085,"about_ca_system_score_gemma":0.000093320145,"threshold_uncertainty_score":0.8859727},"labels":[],"label_agreement":null},{"id":"W4256674571","doi":"10.1517/eotp.13.7.979.22985","title":"Epilepsy drug review: patent activity from 1999 to 2002","year":2003,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Drug; Epilepsy; Pharmacology; Drug development; Medicine; Business; Psychiatry","score_opus":0.17062245208788937,"score_gpt":0.33226603316605974,"score_spread":0.16164358107817037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256674571","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13445053,0.62454265,0.004326316,0.06019541,0.019984692,0.0045797336,0.002359498,0.00044747005,0.1491137],"genre_scores_gemma":[0.78931385,0.12211672,0.00025765243,0.08655911,0.0003685197,0.00023626452,0.000042301926,0.00008661969,0.0010189633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797744,0.00009431571,0.00063037744,0.00069777697,0.00007326147,0.00052685867],"domain_scores_gemma":[0.9986452,0.00008638442,0.00025295714,0.00063305127,0.000022554255,0.0003598856],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00046476396,0.00031960555,0.0006048853,0.00015004275,0.00012547753,0.000058195255,0.00035416946,0.00009876434,0.0037607115],"category_scores_gemma":[0.00006983469,0.000332518,0.00022008373,0.00020683337,0.000034059107,0.00014839001,0.000053196556,0.00023101109,0.008814076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060512003,0.004090342,0.029112028,0.00021650529,0.0012287801,0.000016868913,0.003172449,0.00018148206,0.0020071846,0.21418634,0.50546366,0.23971921],"study_design_scores_gemma":[0.00081860286,0.00008121943,0.0056225862,0.00013692743,0.0000022496624,0.0000011515227,0.0000102990725,0.0003391176,0.001496792,0.0065655983,0.9844742,0.0004512521],"about_ca_topic_score_codex":0.0003936263,"about_ca_topic_score_gemma":0.0000032660405,"teacher_disagreement_score":0.6548633,"about_ca_system_score_codex":0.00019598169,"about_ca_system_score_gemma":0.00002275695,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W4386945206","doi":"10.1080/13543776.2023.2262136","title":"Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of British Columbia; University of Alberta","funders":"","keywords":"Trk receptor; Medicine; Precision medicine; Pharmacology; Bioinformatics; Cancer research; Computational biology; Biology; Receptor; Internal medicine; Neurotrophin; Pathology","score_opus":0.11039378927360463,"score_gpt":0.3584458892396905,"score_spread":0.24805209996608588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386945206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014490848,0.99421793,0.000021214566,0.00011096738,0.0041898713,0.0010248753,0.00016031486,0.0000586768,0.00007121069],"genre_scores_gemma":[0.00014119738,0.9942414,0.000063473046,0.00031164786,0.00086214516,0.00024603328,0.0030287053,0.0001581471,0.0009472123],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969854,0.0004120122,0.00092654134,0.000808672,0.00045897215,0.000408432],"domain_scores_gemma":[0.9982476,0.000025810863,0.00060179527,0.00083014317,0.00013203944,0.00016260886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002811658,0.00060875795,0.00097306643,0.00020670853,0.00009795088,0.000031129992,0.00050962885,0.0005768192,0.00019541003],"category_scores_gemma":[0.00007591548,0.00049288187,0.0005946186,0.0005103305,0.00010159044,0.000006848461,0.00021156263,0.00029593956,0.000481165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017249736,0.00033713877,0.000005343734,0.0009379995,0.0005111337,0.0000042207366,0.000046807454,9.946278e-7,0.0058333236,0.00008690486,0.033383176,0.95868045],"study_design_scores_gemma":[0.000506976,0.0006497138,0.000002370254,0.0027986798,0.00002627678,0.0000051706834,0.00003112226,0.000002829586,0.011013687,0.000016285998,0.9844499,0.00049694424],"about_ca_topic_score_codex":0.000023505387,"about_ca_topic_score_gemma":0.0000010552772,"teacher_disagreement_score":0.9581835,"about_ca_system_score_codex":0.00008824098,"about_ca_system_score_gemma":0.00023813198,"threshold_uncertainty_score":0.9997523},"labels":[],"label_agreement":null},{"id":"W4398778278","doi":"10.1080/13543776.2024.2358818","title":"Type II &amp; III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Therapeutic Patents","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of Alberta; University of British Columbia","funders":"","keywords":"Trk receptor; Tropomyosin; Receptor; Tropomyosin receptor kinase A; Chemistry; Tropomyosin receptor kinase C; Kinase; Biochemistry; Pharmacology; Cell biology; Biology; Platelet-derived growth factor receptor; Neurotrophin","score_opus":0.039680297802238126,"score_gpt":0.29998558509465406,"score_spread":0.2603052872924159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398778278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8639159,0.12200964,0.0029356477,0.002524996,0.006783312,0.0011147877,0.00011978543,0.00017764299,0.00041826727],"genre_scores_gemma":[0.99014705,0.006884142,0.00027651183,0.000692917,0.00053098606,0.000055516626,0.00064285385,0.000052967,0.00071705884],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998451,0.00012246727,0.0003736162,0.00048590032,0.00030098372,0.00026602842],"domain_scores_gemma":[0.9992953,0.00000953386,0.000098720695,0.00039537426,0.000090864145,0.00011022757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020147869,0.00024957667,0.00020641775,0.000100012294,0.00012190977,0.000029889658,0.00017347727,0.000177301,0.0005014252],"category_scores_gemma":[0.000019093695,0.00021432807,0.00017428045,0.00025200326,0.000071822185,0.000008531885,0.000110259956,0.00012905295,0.000090039],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004461607,0.00020097209,0.000044435063,0.000026117694,0.00013195215,0.000003038644,0.00024559163,0.00003807181,0.9398945,0.00030706453,0.0072718663,0.051390223],"study_design_scores_gemma":[0.00065053225,0.00044703248,0.00006004447,0.00017266045,0.0000049331466,0.0000052454916,0.00004594077,0.00015112749,0.48636732,0.00008575688,0.5117794,0.00022999985],"about_ca_topic_score_codex":0.000026807138,"about_ca_topic_score_gemma":0.0000014765711,"teacher_disagreement_score":0.50450754,"about_ca_system_score_codex":0.000042801243,"about_ca_system_score_gemma":0.00008473081,"threshold_uncertainty_score":0.87400454},"labels":[],"label_agreement":null},{"id":"W4402118985","doi":"10.1080/13543776.2024.2400175","title":"Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Drug; Drug discovery; Covalent bond; Pharmacology; Business; Chemistry; Combinatorial chemistry; Medicine; Biochemistry; Organic chemistry","score_opus":0.11110982289387422,"score_gpt":0.3708849694896212,"score_spread":0.25977514659574696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402118985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029930018,0.99215615,0.000015745009,0.0003879148,0.000528197,0.0006793314,0.0004021864,0.00021958687,0.0026178993],"genre_scores_gemma":[0.061641138,0.92868364,0.000014132645,0.00014937801,0.00047872314,0.0018101346,0.004531578,0.0001938897,0.0024973834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942538,0.00025109222,0.0017456086,0.0019914417,0.0008641753,0.0008938598],"domain_scores_gemma":[0.9970886,0.0004687917,0.0007414304,0.0014365744,0.00005245378,0.00021211042],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005184041,0.0012799659,0.0024612662,0.0008816819,0.00016922451,0.0002692978,0.0008742307,0.0006242879,0.00036500455],"category_scores_gemma":[0.000035270332,0.0010426609,0.001436282,0.0034070297,0.000063787884,0.00013685747,0.00019595065,0.0015319895,0.00016528186],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031865045,0.0028513637,0.00028154766,0.005334145,0.0037626538,0.00007043756,0.0020431872,0.00011419941,0.0003045548,0.00015022262,0.0017324906,0.9830365],"study_design_scores_gemma":[0.002775339,0.000106652995,0.000102323604,0.020851241,0.001301565,0.000019725028,0.0007025947,0.0016124094,0.00087806175,0.00010932103,0.96934813,0.0021926626],"about_ca_topic_score_codex":0.00020733423,"about_ca_topic_score_gemma":0.000060348117,"teacher_disagreement_score":0.9808439,"about_ca_system_score_codex":0.0011443235,"about_ca_system_score_gemma":0.00015247334,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W4403781693","doi":"10.1080/13543776.2024.2423023","title":"Ectonucleotidase inhibitors: an updated patent review (2017–2023)","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Chemistry; Pharmacology; Medicine","score_opus":0.1443363722778405,"score_gpt":0.3912386502507594,"score_spread":0.2469022779729189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403781693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007104422,0.9960603,0.0000290178,0.00012624146,0.0023244172,0.0009722621,0.00010866141,0.00008186998,0.00029009234],"genre_scores_gemma":[0.0000824055,0.98819804,0.00002770306,0.002145791,0.0017879892,0.00025452353,0.0065831565,0.00018264496,0.0007377513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669576,0.0004289763,0.000851329,0.0011511336,0.00037658712,0.0004962098],"domain_scores_gemma":[0.9982659,0.000012291966,0.00032644253,0.001066742,0.00008659901,0.00024199863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031029253,0.0008539789,0.0011855505,0.00015797664,0.00011293445,0.00007790655,0.0006045523,0.00054105825,0.00028716295],"category_scores_gemma":[0.000015773256,0.0006113176,0.0007373942,0.0002955092,0.00005748758,0.000009445196,0.00019797708,0.00042911182,0.0007432139],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036084315,0.00031921337,8.1227256e-7,0.005428635,0.0007696273,0.000052250252,0.000033114018,9.959169e-7,0.00020373511,0.00003493174,0.29865912,0.69446146],"study_design_scores_gemma":[0.00023528426,0.00046367737,3.644412e-7,0.024581455,0.00018202797,0.00008710374,0.0000099637355,0.000007455558,0.00012712469,0.000012285766,0.97359043,0.0007028117],"about_ca_topic_score_codex":0.000019382494,"about_ca_topic_score_gemma":3.117058e-7,"teacher_disagreement_score":0.69375867,"about_ca_system_score_codex":0.00006358915,"about_ca_system_score_gemma":0.00019741966,"threshold_uncertainty_score":0.9996338},"labels":[],"label_agreement":null},{"id":"W4412046485","doi":"10.1080/13543776.2025.2529217","title":"Recent advances in tropomyosin receptor kinase (TRK) inhibitors: a 2023–2024 patent landscape review","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia; McMaster University","funders":"","keywords":"Trk receptor; Kinase; Receptor; Pharmacology; Medicine; Chemistry; Internal medicine; Biochemistry","score_opus":0.11193860631188104,"score_gpt":0.39808832094260943,"score_spread":0.28614971463072836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412046485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.9246585e-7,0.9862953,0.000011555543,0.0012871439,0.007100411,0.0027768873,0.00014434001,0.00010091404,0.0022827843],"genre_scores_gemma":[0.000002051349,0.99202037,0.000051194766,0.0027281642,0.0008126894,0.001287971,0.001250004,0.00009864286,0.0017489004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563056,0.000493128,0.0016271909,0.0010335927,0.000636395,0.00057915977],"domain_scores_gemma":[0.99794346,0.00023763822,0.00054784626,0.0008596729,0.00017562673,0.00023572869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003868449,0.0008907121,0.0026871632,0.00072920386,0.00010755525,0.000044750934,0.00031550677,0.0003926464,0.002865124],"category_scores_gemma":[0.00018405994,0.0006409587,0.00094519515,0.0013280855,0.00005055798,0.00013583277,0.0000980728,0.0010436188,0.0005448406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121505225,0.0008029444,0.000009012993,0.016219864,0.00018326304,0.000023194883,0.000052113435,4.3519432e-7,0.00001565531,0.00002459175,0.030987727,0.9515597],"study_design_scores_gemma":[0.0008079099,0.000448893,0.0000020681364,0.27763778,0.00011137843,0.000026253876,0.00003475584,0.0000061072465,0.000030069288,0.00000767533,0.72048974,0.0003973609],"about_ca_topic_score_codex":0.00002330042,"about_ca_topic_score_gemma":0.0000036005883,"teacher_disagreement_score":0.95116234,"about_ca_system_score_codex":0.00056980824,"about_ca_system_score_gemma":0.0005212297,"threshold_uncertainty_score":0.99960417},"labels":[],"label_agreement":null},{"id":"W4413414271","doi":"10.1080/13543776.2025.2548586","title":"Implementation and outcomes of China’s drug patent linkage system: lessons from international experience","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Drug; Linkage (software); China; Pharmacology; Medicine; Process management; Public relations; Political science; Biology; Gene; Genetics","score_opus":0.26169260884227696,"score_gpt":0.38222949783615956,"score_spread":0.1205368889938826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413414271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028489827,0.98929214,0.00017901315,0.0003141861,0.00617605,0.0011451879,0.00013541656,0.000114754446,0.0023583418],"genre_scores_gemma":[0.027104655,0.9701128,0.000024910963,0.0007089568,0.00050532905,0.00026810405,0.00091959775,0.00005158711,0.00030403063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759024,0.00009358976,0.0008967946,0.0006253944,0.0005025886,0.00029137236],"domain_scores_gemma":[0.9986519,0.00012314461,0.00070269516,0.00038678505,0.00011321767,0.000022232292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021145615,0.00054326985,0.0011076736,0.00045189462,0.00018703005,0.0001913845,0.0006344148,0.00019015961,0.00034599053],"category_scores_gemma":[0.000032524746,0.0003852836,0.00032811344,0.0002499071,0.00006169462,0.00036716115,0.0003075091,0.00024201637,0.00012028261],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004279183,0.00015948074,0.0004829583,0.0029186246,0.0004958106,0.0000033678234,0.0007737098,0.0000010035666,0.0000035034595,0.001444981,0.000778722,0.99289507],"study_design_scores_gemma":[0.0008543826,0.000023605804,0.0009926679,0.012692242,0.00011484808,0.0000014933,0.001275516,0.00022431635,0.000019352292,0.000084736814,0.98316747,0.0005493511],"about_ca_topic_score_codex":0.0021699355,"about_ca_topic_score_gemma":0.000011559423,"teacher_disagreement_score":0.9923457,"about_ca_system_score_codex":0.00011316046,"about_ca_system_score_gemma":0.000051327686,"threshold_uncertainty_score":0.9998599},"labels":[],"label_agreement":null},{"id":"W4417222214","doi":"10.1080/13543776.2025.2602703","title":"Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with <i>in vitro</i> activity against <i>Acinetobacter baumannii</i> : a patent evaluation (US 2025/0223303)","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Therapeutic Patents","topic":"Synthesis of β-Lactam Compounds","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University","keywords":"Scope (computer science); Context (archaeology); Serine; Tricyclic; Enzyme; Boronic acid","score_opus":0.07328824272488464,"score_gpt":0.3353653821753039,"score_spread":0.26207713945041927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417222214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015766975,0.97745377,0.000008474243,0.00033602116,0.0009861189,0.0019047708,0.00011678105,0.00024914357,0.0031779585],"genre_scores_gemma":[0.06211622,0.93369037,0.000034376808,0.0005638029,0.0004124423,0.0015683657,0.0007784167,0.0002493028,0.00058670854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928868,0.0008556919,0.0013824248,0.0020969724,0.0016019257,0.0011762063],"domain_scores_gemma":[0.99616635,0.00061652536,0.0010305302,0.0017026286,0.00012875696,0.00035519642],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00082384504,0.0018647653,0.0030535138,0.00079156307,0.00027970097,0.0002504822,0.0008496865,0.0009077556,0.00029105615],"category_scores_gemma":[0.00010244634,0.001497823,0.0007339066,0.0008607183,0.00016331888,0.00041574758,0.00032217143,0.0012974562,0.000082134706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001051723,0.001108379,0.00013009187,0.003038492,0.0010826444,0.00003977486,0.00014951351,0.000005373074,0.0032316817,0.0000047552935,0.00014324863,0.9900143],"study_design_scores_gemma":[0.0066001797,0.0004256525,0.0002543729,0.022349508,0.00063333655,0.000084350875,0.00009066035,0.00036693297,0.015981572,0.000046117653,0.9506602,0.002507095],"about_ca_topic_score_codex":0.0002033851,"about_ca_topic_score_gemma":0.000015433285,"teacher_disagreement_score":0.9875072,"about_ca_system_score_codex":0.0017635599,"about_ca_system_score_gemma":0.00086814153,"threshold_uncertainty_score":0.9994097},"labels":[],"label_agreement":null}]}